Aptose Biosciences Inc. (TSX:APS)
Canada · Delayed Price · Currency is CAD 2.140
-0.110 (-4.89%)
Jun 30, 2026, 2:43 PM EST
Aptose Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
Tuspetinib, a mutation-agnostic oral therapy, is showing high response rates and durable remissions in newly diagnosed AML patients, including those with high-risk mutations, with no significant safety concerns. Pivotal trial dose selection is expected this year, with major data presentations upcoming.
Fiscal Year 2024
-
Shareholders approved the issuance of common shares underlying certain warrants and authorized potential adjournment to solicit more proxies if needed. No additional business or questions were raised, and all resolutions passed by majority vote.